Our solution: develop prostate cancer therapeutics with a new mode of action 

Selective payload delivery via PSMA

PSMA expression is significantly higher in primary PCa as compared to benign tissue and can serve as a vehicle for chemotherapy delivery

Degradation of prostate cancer driving proteins

Harnessing the intracellular degradation machinery to remove essential proteins and trigger prostate cancer cell death

Selective and targeted therapy to trigger cancer cell death

The combination of PSMA targeting and the  selective elimination of key cancer driving proteins can provide superior efficacy and bring benefits to patients